DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
1-Year Return
13.6%
This Quarter Return
+23.38%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.48B
AUM Growth
+$624M
(+22%)
Cap. Flow
+$477M
Cap. Flow
% of AUM
13.71%
Top 10 Holdings %
Top 10 Hldgs %
38.49%
Holding
77
New
19
Increased
14
Reduced
16
Closed
11
Top Buys
| 1 |
Amgen
AMGN
|
$156M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$124M |
| 3 |
Dyne Therapeutics
DYN
|
$72.5M |
| 4 |
MindMed
MNMD
|
$62.7M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$58.8M |
Top Sells
| 1 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$52.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
$48.2M |
| 3 |
RAPT Therapeutics
RAPT
|
$44.6M |
| 4 |
Arcellx
ACLX
|
$40.2M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$34.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Travere Therapeutics
TVTX
$1.89B
| $56.8M | 1.63% |
7,370,000
| – | – |
|
|
VRNA
27
Verona Pharma
VRNA
$9.19B
| $51.3M | 1.47% |
3,187,415
| – | – |
|
28
Kymera Therapeutics
KYMR
$3.02B
| $50.7M | 1.45% |
+1,262,246
| New | +$50.7M |
|
29
Invivyd
IVVD
$209M
| $48.6M | 1.39% |
+10,953,937
| New | +$48.6M |
|
30
Spyre Therapeutics
SYRE
$1.03B
| $46M | 1.32% |
1,213,420
-739,340
| -38% | -$28M |
|
31
Nurix Therapeutics
NRIX
$697M
| $44.1M | 1.26% |
2,997,830
| – | – |
|
32
HilleVax
HLVX
$105M
| $42.8M | 1.23% |
2,572,460
-327,540
| -11% | -$5.45M |
|
33
Editas Medicine
EDIT
$227M
| $41M | 1.17% |
5,527,290
+54,204
| +1% | +$402K |
|
34
Fate Therapeutics
FATE
$112M
| $40.9M | 1.17% |
+5,572,607
| New | +$40.9M |
|
35
Terns Pharmaceuticals
TERN
$618M
| $40M | 1.15% |
6,100,000
| – | – |
|
36
enGene Holdings
ENGN
$256M
| $38.1M | 1.09% |
+2,250,000
| New | +$38.1M |
|
37
Tourmaline Bio
TRML
$645M
| $36.5M | 1.05% |
1,595,400
-220,454
| -12% | -$5.05M |
|
38
Olema Pharmaceuticals
OLMA
$436M
| $36.5M | 1.05% |
3,225,419
+1,294,525
| +67% | +$14.7M |
|
|
SLN
39
Silence Therapeutics
SLN
$247M
| $35.5M | 1.02% |
1,643,881
-307,699
| -16% | -$6.65M |
|
40
Pacific Biosciences
PACB
$372M
| $26.3M | 0.75% |
7,000,000
| – | – |
|
|
CYBN
41
Cybin
CYBN
$141M
| $24M | 0.69% |
+1,529,988
| New | +$24M |
|
42
Alector
ALEC
$285M
| $22.7M | 0.65% |
+3,769,386
| New | +$22.7M |
|
43
Nuvalent
NUVL
$5.74B
| $20.6M | 0.59% |
274,512
-175,488
| -39% | -$13.2M |
|
|
AGEN
44
Agenus
AGEN
$137M
| $18.4M | 0.53% |
1,584,877
| – | – |
|
45
Pyxis Oncology
PYXS
$99.8M
| $17.8M | 0.51% |
+4,184,100
| New | +$17.8M |
|
46
Nektar Therapeutics
NKTR
$684M
| $17.2M | 0.49% |
1,226,667
| – | – |
|
47
Immunovant
IMVT
$2.81B
| $15.9M | 0.46% |
493,352
-506,648
| -51% | -$16.4M |
|
48
Neumora Therapeutics
NMRA
$264M
| $13.8M | 0.39% |
+1,000,000
| New | +$13.8M |
|
49
Repare Therapeutics
RPTX
$72.6M
| $12.6M | 0.36% |
2,684,344
-308,387
| -10% | -$1.45M |
|
50
Scholar Rock
SRRK
$3.12B
| $12.1M | 0.35% |
680,000
-331,829
| -33% | -$5.89M |
|